In a phase 3 trial, once-daily oral orforglipron induced significant, dose-dependent weight loss over 72 weeks in adults with ...

Pharmaceutical companies are racing to develop a GLP-1 weight-loss drug in pill form. Novo Nordisk says its oral semaglutide pill led to "significant weight loss" in a trial.

Makers of GLP-1 drugs, including Novo Nordisk, Eli Lilly and others, are close to releasing daily pills to help shed pounds ...

Obesity is one of the most stubborn health challenges of our time, linked with diabetes, heart disease, sleep problems, and ...

It's a trending topic: weight loss medication. But which one might be right for you? 7 News sat down with doctors from Bon ...

The results of this landmark trial are particularly significant, as oral therapies for obesity could improve both access to ...

Production is under way and the pill, which helped patients lose an average 16.6% of their weight, is pending regulatory approval in the U.S.

The drug. orforglipron, works on the same receptor as semaglutide (Ozempic/Wegovy), but can be taken without restrictions on food or water intake.

Novo Nordisk's experimental Wegovy pill showed a 16.6% weight-loss in a late-stage study, according to data published in The ...

Eli Lilly's bid for approval for an experimental weight-loss pill got a boost on Wednesday with new clinical trial data, and ...

When I think about food noise, I’m flung back to the height of my eating disorder, when I was paralyzed by the thought of ...